|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase 1 Multicenter Study Evaluating the Safety and Tolerability of GCC19CART for Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Study ICT-GCC19CART-US-001 (CARAPIA-1) is a Phase 1 study evaluating the safety, tolerability, clinical activity, pharmacokinetics and pharmacodynamics of GCC19CART in subjects with relapsed or refractory metastatic colorectal cancer.
100 Clinical Results associated with Innovative Cellular Therapeutics, Inc.
0 Patents (Medical) associated with Innovative Cellular Therapeutics, Inc.
100 Deals associated with Innovative Cellular Therapeutics, Inc.
100 Translational Medicine associated with Innovative Cellular Therapeutics, Inc.